Genprex, Inc. (GNPX) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer.
(0.2)
Genprex, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Debt-Equity Ratio (DER)GNPX equity is higher than it's debt. |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthGNPX has never had growing revenue. |
|
Net Income GrowthGNPX has never had growing net income. |
|
Price to Book (PBV) RatioOvervalued price-to-book. GNPX stock price is overvalued by more than 2x the price-to-book value. |
|
Net IncomeGNPX never has positive net income for 2 years. |
|
Dividend YieldGNPX has low dividend yield (0%). |
|
Return of AssetsGNPX has low return of asset (-75.66%). |
|
Return of EquityGNPX has low return of equity (-65.58%). |
|
RevenueGNPX never has positive revenue for 2 years. |
|
Return of Invested CapitalGNPX has low ROIC. |
Competitors
Genprex, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 0 USD
- Cost
- 19,600,757 USD
- Net Income
- -19,595,624 USD
- Profit Margin
- 0%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -14,316,624 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 1039.79% |
Long Term Liabilities
| Liquidity/Current Ratio | 1070.61% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -3x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 1070.61% |
| Cash Ratio | 1038.37% |
| Debt Ratio | 8.21% |
| Debt-Equity Ratio (DER) | 8.94% |
| Net Profit Margin (NPM) | 0% |
| Return of Assets (ROA) | -75.66% |
| Return of Equity (ROE) | -65.58% |
| Return on Capital Employed (ROCE) | -82.55% |
| Days of Sales Outstanding (DSO) | 0 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Genprex, Inc. Executives
CEO
- CEO Name
- Mr. J. Rodney Varner
Management
Genprex, Inc. Profile
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Additional Information
- Company name
- Genprex, Inc.
- Symbol
- NASDAQ:GNPX
- Exchange
- NASDAQ Capital Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
1601 Trinity St Bldg B
Austin
TEXAS
US
78746 - Website
- https://www.genprex.com